Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1

Interventions

Cisplatin 32Gemcitabine 21Radiotherapy, Intensity-Modulated 16toripalimab 14Capecitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiotherapy 7Drug Therapy 7pembrolizumab 6Platinum 6Nivolumab 6Immune Checkpoint Inhibitors 61,2-diaminocyclohexaneplatinum II citrate 6Docetaxel 5tislelizumab 4spartalizumab 4camrelizumab 4sintilimab 3anlotinib 3Immunoglobulin G 3Disulfides 3Carboplatin 3nimotuzumab 2fludarabine 2atezolizumab 2Taxes 2Radiation 2Phantoms, Imaging 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × penpulimab × 1 year × Clear all
NCT05563480 2026-04-07

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
47 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡